RXI Pharma's (RXII) Samcyprone Receives FDA Orphan Drug Designation as Malignant Melanoma Stage IIb to IV Treatment
Tweet Send to a Friend
RXI Pharma (NASDAQ: RXII) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation of its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
